MLD granted second Pre-IND meeting with the FDA for PPI-1040 and treatment of RCDP

SASKATOON, SK, CANADA. MLD, a developer of advanced plasmalogen-based therapeutic products, is pleased to announce that it has been granted a second Type B pre-IND meeting with the FDA to discuss details surrounding the development of PPI-1040 for the treatment of RCDP. The meeting is scheduled for the last week in January, 2019, and focuses specifically on the proposed nonclinical development plan. "This meeting represents another step towards the ultimate goal of improving the lives of patients with RCDP," says Dr. Tara Smith, VP of Therapeutics, "and we are looking forward to the FDA's feedback on our proposed animal studies, and beginning the nonclinical safety and pharmacology program this coming year."


About MLD

MLD is a Canadian health prevention company developing novel plasmalogen replacement compounds for the treatment of various disorders associated with plasmalogen deficiency, including RCDP, Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis, as well as companion screening tests that detect metabolic risk for chronic diseases including neurodegenerative disorders and cancer.

MLD's Safe Harbor Statement
This document may contain “forward-looking statements” within the meaning of Canadian securities legislation. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective”, and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Forward-looking statements contained in this release are necessarily based on assumptions and information that, while considered reasonable to us, are inherently uncertain. Readers should not place undue reliance on any forward-looking statements. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made.